Pfizer Obesity Treatment Halted After Clinical Trials
April 14, 2025
Pfizer obesity treatment, a once-promising potential solution for weight management, has faced recent setbacks as the company discontinues its development of danuglipron, an oral drug designed to combat obesity.Announced on Tuesday, this decision follows serious concerns related to a potential drug-induced liver injury experienced by a participant in the clinical trials for obesity.
Read more
Medicare Obesity Treatment: Trump Administration’s Decision
April 5, 2025
Medicare obesity treatment has become a crucial topic in the discussion about healthcare coverage for millions of Americans struggling with weight-related issues.Despite the demand for obesity medications like Wegovy and Zepbound, the Trump administration opted not to include these vital treatments in the Medicare program under Part D, leaving many without access to effective weight loss drugs.
Read more